Fulvestrant: A New Treatment Option for Advanced Breast Cancer - Tolerability Versus Existing Agents
October 2005
in “
Annals of Oncology
”
Studysummary This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on annalsofoncology.org →